Survival after gamma interferon intratumoral injections in a model of hepatocarcinoma

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 1115-1120

  Peyrègne, Vincent ^a,b,e   Quash, Gerard ^b   Isaac, Sylvie ^a   Chantepie, Jacqueline ^b   Akiba, Hitoshi ^c   Scoazec, Jean Yves ^d   Gilly, Francois Noël ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSERM   (France)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Ectopic model; Hepatocarcinoma; Interferon; Survival

Indexed keywords

PHOSPHATE; RECOMBINANT GAMMA INTERFERON; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LIVER CELL CARCINOMA; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; STAINING; STATISTICAL SIGNIFICANCE; TUMOR NECROSIS;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE; CELL NUCLEUS; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; LIVER NEOPLASMS; MICE; MICE, NUDE; NECROSIS; NEUTROPHILS; SURVIVAL ANALYSIS;

EID: 3042558268     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C, Ferry N: In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996; 7:1503-1514.
2. Venook A: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12:1323-1334.
3. Aguayo A, Patt YZ: Liver cancer. Clin Liver Dis 2001; 5:479-507.
4. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH: Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91:1479-1486.
5. Baratin M, Ziol M, Romieu R, Kayibanda M, Gouilleux F, Briand P, Leroy P, Haddada H, Renia L, Viguier M, Guillet JG: Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 2001; 8:193-202.
6. Bromberg JF, Horwath CM, Wen Z, Schreiber ED, Darnell JE: Transcriptionally active Stat 1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc Natl Acad Sci USA 1996; 93:7673.
7. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP: Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 1998; 77:107-113.
8. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE: Cancer dormancy. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1999; 162:2842-2849.
9. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H: CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999; 96:8633-8638.
10. Farrar MA, Schreiber RD: The molecular cell biology of interferon gamma and its receptor. Annu Rev Immunol 1993; 11:571-611.
11. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K: The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243:1464-1466.
12. Karpoff HM, Tung C, Ng B, Fong Y: Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology 1996; 24:374-379.
13. Akbar SM, Kajino K, Tanimoto K, Yamamura K, Onji M, Hino O: Unique features of dendritic cells in IFN-gamma transgenic mice: relevance to cancer development and therapeutic implications. Biochem Biophys Res Commun 1999; 259:294-299.
14. Coughlin CM, Salhany KE, Gee MS, La Temple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM: Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9:25-34.
15. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161:927-932.
16. Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H: Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Ther 2002; 9:537-546.
17. Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC: Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002; 180:36-42.
18. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, Menard O, Mignot P, Dabouis G, Douillard JY: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460-2467.
19. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V: The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am 1998; 4:162-167.
20. Rustgi VK: Epidemiology of hepatocellular carcinoma. Ann Intern Med 1998; 108:390-401.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
22. Xu X, Fu XY, Plate J, Chong AS: IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58:2832-2837.
23. Mehier H: Device for directly delivering an active substance within a cell tissue, means for implanting said device and appliances for injecting active substances into said device. Patent WO00/29055.